logo
Health Rounds: Blood test finds early ovarian cancer

Health Rounds: Blood test finds early ovarian cancer

Reuters18 hours ago
Aug 15 (Reuters) - An experimental blood test detects early-stage ovarian cancer in patients with vague symptoms that would likely be misdiagnosed using currently available methods, researchers said in a new report.
Ovarian cancer is the fifth leading cause of cancer-related deaths among women, largely due to delays in diagnosis until after the disease has spread in the body, at which point it's harder to treat, according to the researchers.
More than 90% of patients with early-stage ovarian cancer experience symptoms that can be mistaken for benign conditions, such as bloating, abdominal pain, and digestive issues.
Not only have there been no reliable blood tests for these patients, but existing invasive tests often miss early-stage ovarian tumors, the researchers noted inCancer Research Communications, opens new tab.
Using machine learning tools, the researchers identified multiple biomarkers - from across a wide range of molecules and processes in the body - that could be combined into a single test that detects all sub-types of the disease, at all stages, they said.
Trialed at a large medical center on blood samples from nearly 400 women with possible symptoms of ovarian cancer, the test was 92% accurate at identifying those with any stage of ovarian cancer and 88% accurate at identifying those with Stage I or Stage II disease, according to the report.
Oriana Papin-Zoghbi, chief executive officer of the company developing the new test -Denver, Colorado-based AOA Dx - said the findings show its potential to aid 'in making faster, more informed decisions for women who need urgent clarity during a challenging diagnostic process.'
PREVENTING ELDERS' 'LEAKY BRAIN' MIGHT STAVE OFF COGNITIVE DECLINE
The blood-brain barrier gets leakier with age, contributing to memory deficits – and new discoveries of the mechanisms behind this process might lead to new ways of preventing cognitive decline, researchers say.
The blood-brain barrier - a layer of tightly-junctioned cells lining the brain's blood vessels - keeps viruses, bacteria and toxins out while allowing helpful nutrients and chemicals in.
'Basically, it's a mechanism that separates the central nervous system from everything else,' study leader Yulia Komarova of University of Illinois Chicago said in a statement.
In previous research, Komarova and her colleagues found that removing a protein called N-cadherin from the cells lining blood vessels made the vessels leakier in the brain. In a new study published in Cell Reports, opens new tab, her team found that mice without N-cadherin could learn tasks as well as normal mice, but they quickly forgot what they learned.
In further experiments, they found when N-cadherin proteins on neighboring cells interact, they stabilize a protein, called occludin, which helps form the tight junctions in the blood-brain barrier that maintains the integrity of the blood-brain barrier.
Examining human brain tissue collected during epilepsy surgeries, the researchers found that samples from patients in their 40s and 50s had lower levels of N-cadherin and occludin than samples from patients in their late teens and 20s.
Komarova's team is now investigating whether steps in the signaling pathway activated by N-cadherin could be therapeutic targets.
'This paper shows that actually there might be a much bigger therapeutic window for treatment of any age-related cognitive decline condition,' she said.
Previous studies may have underestimated the number of deaths related to wildfire smoke in Europe by as much as 93%, according to a report in The Lancet Planetary Health, opens new tab.
In new research, using daily mortality records from 654 contiguous regions in 32 European countries, researchers found that for every 1 microgram per cubit meter increase in wildfire smoke particles, all-cause mortality rose by 0.7%, respiratory mortality by 1%, and cardiovascular mortality by 0.9%.
Annually since 2004, short-term exposure to wildfire pollution was responsible for an average of 535 deaths from all causes, the researchers calculated – while estimates in previous studies had put that number at around 38 deaths per year, they said.
'Human-driven climate change is one of the main causes of the rising frequency and intensity of wildfires, as it creates favorable conditions for their spread and increases the number of days with very high or extremely high fire risk,' study leader Anna Alari of the Barcelona Institute for Global Health said in a statement.
'Improving estimates of (wildfire smoke related) mortality will help better track the burden of this climate change-related threat to public health.'
A separate study found that as wildfire pollution levels rise, firefighters' hearts work harder, researchers wrote in Circulation Arrhythmia and Electrophysiology, opens new tab.
After fighting the Park Fire in California, firefighters' heart rate at rest would rise by an average of 1.4 beats per minute for every 10-ug/m3 increase in particulate matter.
Although the increase in resting heart rate was modest, and the rate remained within normal levels, even slight elevations have been associated with increased cardiovascular morbidity and mortality over time in large population studies.
(To receive the full newsletter in your inbox for free sign up here)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

I'm 37 but get mistaken for being 19 after using 69p frozen item every day & it gets rid of dark eye circles too
I'm 37 but get mistaken for being 19 after using 69p frozen item every day & it gets rid of dark eye circles too

The Sun

time28 minutes ago

  • The Sun

I'm 37 but get mistaken for being 19 after using 69p frozen item every day & it gets rid of dark eye circles too

WHEN it comes to maintaining a youthful complexion, many typically think of pricey Botox treatments. But according to one thrifty beauty buff, the answer can be found in your fridge - and it's a fan favourite in salads. 2 Amal K., from San Francisco, may be almost 40 - but at 37 she looks so radiant and wrinkle-free that many mistaken her for a teenager. The dark-haired beauty regularly shares her top tips for skincare, such as eating sardines - however, Amal recently stunned with an easy hack that costs less than £1. As well as eating a nutrient-dense diet, the TikToker likes to ensure her skincare routine is top tip - and there's one key step that might surprise you. To kickstart her morning skincare, Amal likes to use a frozen cucumber slashed in half that's been sitting in the freezer overnight. In the now-viral-video, the savvy beauty buff explained she used it as ''a natural Gua Sha''. This traditional Chinese medicine technique involves scraping the skin with a smooth-edged tool to relieve hypertension and improve circulation. The method has become a hit on social media ever since it took off - and even Kendal Jenner swears by this ancient technique. Meanwhile, using a frozen cucumber on your face can offer temporary de-puffing and soothing effects due to its cold temperature - ideal for that morning puffiness. ''I am 37 years old, and I have never had Botox or fillers. One thing I do daily is an ice facial - but today, we are going to use a frozen cucumber'' she said in another clip. ''Before you start, make sure your face is nice and clean. ''Cucumber contains vitamin K, so it is just going to help curb the appearance of dark circles, help the lymphatic around your eyes and reduce the appearance of puffiness. ''We all love that, right? It also helps blood circulation, brightens your skin, minimises pores.'' After you are done, she said, don't throw the whole cucumber - simply cut the top little piece off and throw the remaining cucumber back in the freezer for use again. ''It's good up to 3 weeks,'' she said in the comments. Why is turmeric good for anti-ageing? A study published in the Asia Pacific Journal of Clinical Nutrition suggests that turmeric and curcumin may help prevent DNA damage and aid in DNA repair. This is promising news for disease prevention and slowing the ageing process. It also: Boosts Collagen Production: Collagen is a protein that maintains the skin's elasticity and firmness. As we age, collagen production decreases, leading to wrinkles and sagging skin. Turmeric helps stimulate collagen synthesis, thereby promoting firmer and more youthful skin. Improves Skin Health: Turmeric has been shown to improve various skin conditions, such as acne, psoriasis, and eczema. Its antibacterial and anti-inflammatory properties help soothe the skin, reduce redness, and promote a clearer complexion. Next, let the cucumber water sit on your face for a few minutes, before splashing your face with cold water - and continue with the rest of the routine. If you've run out of cucumber, you can snap up this salad - and skincare - staple for a mere 69p from Aldi and other supermarkets. The clip, posted under the username @ amalkzad has taken the internet by storm, winning the stunner a whopping 2.1million views. As 152k users gave it a like, close to 800 people flooded to comments, where many refused to believe her age. ''She don't look 30, she don't look so, she looks 19,'' wrote one person. A fellow beauty buff was clearly so impressed by the results they were keen to give the hack a go themselves. ''Girl you look 19,'' someone else wrote.

Experimental drug eliminates aggressive breast, skin cancer in small trial
Experimental drug eliminates aggressive breast, skin cancer in small trial

Medical News Today

timean hour ago

  • Medical News Today

Experimental drug eliminates aggressive breast, skin cancer in small trial

Scientists have developed a new cancer drug that can be injected directly into tumors. The treatment, an enhanced CD40 agonist, was successful in its first trial of 12 human participants. Six people in the group saw their tumors shrink, while two participants saw their cancer go completely into remission. The National Institutes of Health project that doctors will diagnose at least 2 million new cancer cases and that 600,000 people will die from cancer in 2025 in the United improving cancer death rates, this prediction highlights the need to continue developing more effective treatments. Researchers from Rockefeller University made headway in this area with the completion of their human phase 1 study. They tested a new CD40 antibody drug, 2141-V11, designed to shrink tumors and reduce side new drug had promising results, shrinking tumors in half the patients and completely eliminating cancer in two cases, while not causing serious side effects. The study appears in the journal Cancer Cell.A new approach to cancer immunotherapyMany cancer treatments exist, and sometimes treatment can be as simple as removing the tumor or lesion for localized cancers. In cases where the cancer is metastatic and has spread, more aggressive treatments are necessary. Some types of more aggressive cancer treatments include: radiation therapychemotherapyhormone American Cancer Society describes immunotherapy as a 'treatment that uses the body's immune system, usually your own, to attack cancer.' There are several types of immunotherapy, such as immune checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies. Researchers in the new study focused on immunotherapy — specifically, the CD40 agonist antibody drug class, a type of monoclonal antibody treatment. It works by activating the CD40 receptor and causing an immune system response. According to the study authors, research on CD40 has not been successful in human trials in the past and has caused serious side effects. This led the scientists to create an engineered form of CD40 called 2141-V11. The drug was designed to improve the issues with CD40 and reduce systemic inflammation and liver toxicity. The scientists also decided to inject the treatment directly into the tumor instead of administering it intravenously. For the human study, the researchers recruited 12 participants, and everyone in the group had metastatic cancers including melanoma and breast cancer. The participants ranged from ages 42 to participants received injections of 2141-V11 into their tumors every 3 weeks, with an increased dosage each results with limited toxicityThroughout the 2141-V11 treatments, the researchers monitored the side effects and bloodwork of the participants. They were especially concerned with the participants' platelet count and liver enzymes since these would indicate a treatment-related adverse event (TRAE). By the end of the treatment, ten participants experienced adverse events, and seven experienced TRAEs. However, none of the patients experienced any TRAEs higher than grade 3, and the researchers considered the drug 'well tolerated.' Most of the side effects were mild and included fever and issues where the drug was injected. Three participants had severe adverse events, but the researchers did not consider them TRAEs. One participant had to be hospitalized because of a urinary tract infection, and another had shortness of breath related to chronic heart failure. No serious dose-limiting toxicities occurred, and the participants' liver and platelet levels were stable throughout treatment. Additionally, cancer tumors shrank in six of the participants, and two participants went into complete remission. One of the participants who went into remission had melanoma, and the other had breast cancer. The researchers noted that not only did their tumors shrink, but tumors in the rest of the body disappeared. Wael Harb, MD, a board-certified hematologist and medical oncologist at MemorialCare Cancer Institute at Orange Coast and Saddleback Medical Centers, spoke with Medical News Today and explained how the cancer drug works.'This drug (2141-V11) is an engineered antibody that flips a key 'ON' switch (CD40) on immune cells inside a tumor,' said Harb, who was not involved in the recent trial. 'It's injected directly into one tumor, where it organizes immune cells into mini lymph nodes called tertiary lymphoid structures (TLS).' 'Those act like on-site training camps that activate cancer-killing T-cells, which then travel through the body to attack tumors that weren't injected,' Harb he noted that the drug's safety profile was encouraging, he emphasized that larger trials are needed. 'Twelve patients are too few to draw firm safety conclusions across cancers–larger trials are needed and are already underway,' the oncologist is next for 2141-V11?Study author Juan Osorio, MD, director Of Clinical Operations And Translational Immunology at Rockefeller University, spoke with MNT and discussed the future of the research with 2141-V11. 'We look forward to the results of several ongoing phase 2 studies nationwide, targeting difficult-to-treat cancers, such as malignant gliomas, bladder cancer, and prostate cancer,' said Osorio. Osorio mentioned that early data from the phase 2 studies is 'promising,' but it is not a one-size-fits-all solution for people with cancer. 'Not all patients respond, highlighting the need for rational combination strategies to extend the benefit of this therapy,' Osorio shared. Osorio said the team is currently trying to figure out which biomarkers may predict response to CD40 agonists. 'Furthermore, we want to evaluate in larger cohorts whether TLS or other immune spatial interactions are crucial for effective induction of antitumor immunity. Answering these questions will be critical to fully translate this approach into meaningful and durable clinical benefit for patients.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store